We recently published a list of What Did Jim Cramer Say About These 19 Stocks Recently? In this article, we are going to take ...
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Ocular Therapeutix (NASDAQ:OCUL) stock rises as Needham rates the company a new Buy, citing the potential of its lead candidate, Axpaxli. Read more here.
Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
10d
Zacks Investment Research on MSNBayer Q4 Earnings In Line, Revenues Top on Nubeqa, Kerendia SalesBayer AG BAYRY reported fourth-quarter 2024 core earnings of 28 cents per American Depositary Receipt (ADR), in line with the ...
While Bayer’s consumer and crop science divisions continued to slide—both in the fourth quarter and in 2024 overall—the ...
Earlier this month, the South Korean biosimilar maker secured approval for three other drugs from Europe: Eydenzelt, referencing blockbuster eye disease treatment Eylea; Stoboclo and Osenvelt.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results